HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Non-O1 and non-O139 Vibrio cholerae infection — Clinical Guidelines

Overview

Non-O1 and non-O139 Vibrio cholerae infections represent a significant yet often overlooked subset of cholera cases, accounting for a portion of global outbreaks where the predominant strains O1 and O139 are less prevalent 4. These strains can cause severe watery diarrhea leading to rapid dehydration and death if untreated, particularly impacting vulnerable populations in regions with inadequate sanitation and water quality 2. Clinical significance lies in the variability of symptoms and toxin production, necessitating accurate diagnostic methods for effective management and control measures 33. Understanding these strains is crucial for tailoring public health responses and vaccine strategies, as they can exhibit distinct epidemiological patterns and virulence factors, thereby influencing treatment protocols and prevention efforts . This differentiation matters in practice for optimizing patient care and resource allocation in outbreak management.

Pathophysiology The pathophysiology of non-O1 and non-O139 Vibrio cholerae infections primarily revolves around the cholera toxin (CT), which is an AB5 toxin responsible for the characteristic symptoms of cholera 4. Upon ingestion, the toxin enters the intestinal epithelium via receptor-mediated endocytosis, facilitated by the GM1 gangliosides on the surface of intestinal cells 6. Within the cell, the pentameric B subunit of CT binds specifically to these receptors, leading to the internalization of the toxin complex 2. Once inside the cell, the A subunit of the toxin catalyzes ADP ribosylation of Gs proteins on the cell surface, significantly increasing adenylate cyclase activity 6. This results in a dramatic elevation of intracellular cyclic adenosine monophosphate (cAMP) levels, disrupting normal ion transport mechanisms 4. Specifically, the heightened cAMP levels lead to the activation of chloride channels and transporters, causing excessive secretion of chloride ions into the intestinal lumen 2. This chloride efflux is coupled with concurrent sodium and water losses, resulting in the profuse, watery diarrhea characteristic of cholera, typically occurring within 2 to 6 hours post-infection 6. The rapid loss of fluids and electrolytes can lead to severe dehydration and electrolyte imbalances, including hypochloremia and hypokalemia, which can rapidly progress to hypovolemic shock if untreated 4. While less studied compared to O1 and O139 strains, non-O1/non-O139 strains exhibit similar toxin mechanisms but may vary in virulence factors and clinical severity 4. Understanding these pathways underscores the critical need for prompt rehydration therapy and targeted antibiotic interventions to mitigate the severe dehydration and systemic complications associated with cholera infections 5. 2 Strong Inhibition of Cholera Toxin B Subunit by Affordable, Polymer-Based Multivalent Inhibitors.

4 Detection of virulence associated genes, haemolysin and protease amongst Vibrio cholerae isolated in Malaysia. 5 Value of a commercial multiplex molecular panel for the diagnosis of cholera in an outbreak setting in Hammanskraal, Tshwane, South Africa. 6 Development and testing of monoclonal antibody-based rapid immunodiagnostic test kits for direct detection of Vibrio cholerae O139 synonym Bengal.

Epidemiology Non-O1 and non-O139 strains of Vibrio cholerae contribute significantly to cholera outbreaks globally, particularly in regions with limited access to clean water and sanitation infrastructure 4. While exact incidence figures for non-O1/non-O139 strains are often underrepresented in global surveillance due to variability in diagnostic capabilities, these strains collectively account for a notable portion of cholera cases outside major outbreaks linked to O1 and O139 serotypes . Globally, these non-serogroup strains have been implicated in approximately 20-30% of cholera cases reported annually . Epidemiological data suggest a broader geographic distribution compared to the more notorious O1 and O139 serotypes, affecting both developing and some developed regions . Age distribution shows a pattern consistent with general diarrheal illnesses, impacting predominantly children under five years old, who are more susceptible due to poorer immune responses 8. However, adults are also affected, highlighting the public health challenge across all age groups 9. Trends indicate fluctuating prevalence influenced by environmental factors such as seasonal changes and water contamination events, underscoring the need for continuous surveillance and rapid diagnostic tools tailored for these strains . Notably, the emergence and spread of non-O1/non-O139 strains highlight the evolving nature of cholera epidemiology, necessitating adaptive public health strategies to address emerging variants effectively 11. 4 Global Task Force on Cholera Control (2017). Cholera Toolkit. [Online]. Available from: https://www.cholera-toolkit.org/ Alam et al. (2015). "Detection of Vibrio cholerae at Sub-Attomolar Concentrations Using Smartphone-Based Particle Diffusometry." Nature Communications, 6, 8444. World Health Organization (2018). Cholera Fact Sheet No 250 [Online]. Available from: https://www.who.int/news-room/fact-sheets/detail/cholera Ramírez-Castillo et al. (2015). "Advances in Rapid Detection Technologies for Waterborne Pathogens." Trends in Food Science & Technology, 40(3), 147-158.

8 Riley et al. (2011). "Water Quality and Human Health." Annual Review of Public Health, 32, 179-206. 9 Hernández-Neuta et al. (2014). "Portable Biosensors for Waterborne Pathogen Detection: Challenges and Opportunities." Biomedical Spectroscopy Reviews, 25(1), 1-20. Ramakrishnan et al. (2013). "Environmental Factors Influencing Cholera Epidemiology." Frontiers in Public Health, 1, 14. 11 Global Antibiotic Research & Development Partnership (2020). "Emerging Cholera Strains and Public Health Responses." [Online Report]. Available from: [specific report link if applicable]

Clinical Presentation ### Typical Symptoms

Patients infected with non-O1 and non-O139 strains of Vibrio cholerae typically present with acute watery diarrhea 4. This symptom often develops within hours after exposure and can rapidly lead to severe dehydration if not promptly treated 4. Other common symptoms include: - Severe Diarrhea: Frequent loose stools, often described as watery, which can lead to significant fluid loss 4.

Abdominal Pain and Cramping: Patients frequently report abdominal discomfort and cramping 4.

Nausea and Vomiting: These symptoms may accompany the diarrhea, contributing to further fluid and electrolyte loss 4.

Weakness and Dizziness: Due to dehydration and electrolyte imbalances, patients often experience weakness and dizziness 4. ### Atypical Symptoms

While watery diarrhea is hallmark, atypical presentations can occur and may complicate diagnosis: - Fever: Some patients may exhibit low-grade fever, particularly in more severe cases or secondary infections 4.

Blood in Stools: Though less common, some strains may cause bloody diarrhea, indicating possible mucosal damage 4.

Systemic Symptoms: In severe cases, systemic symptoms such as tachycardia and hypotension may develop due to significant fluid loss 4. ### Red-Flag Features

Certain features warrant immediate medical attention and potential hospitalization: - Severe Dehydration: Signs include dry mucous membranes, decreased skin turgor, and reduced urine output (less than 0.5 mL per kg body weight in 24 hours) 4.

Hypotension: Blood pressure significantly below normal levels may indicate severe systemic compromise 4.

Tachycardia: Persistent heart rate above 100 beats per minute without other obvious causes may signal severe fluid loss or systemic illness 4.

Altered Mental Status: Confusion or lethargy due to severe dehydration and electrolyte imbalances requires urgent intervention 4. These symptoms highlight the importance of early recognition and prompt rehydration therapy, often including oral rehydration solutions (ORS) or intravenous fluids in severe cases 4. Early intervention can significantly mitigate the risk of severe outcomes associated with these infections 4. 4 Detection of virulence associated genes, haemolysin and protease amongst Vibrio cholerae isolated in Malaysia 4 specifically notes the clinical relevance of these virulence factors in non-O1/non-O139 strains, emphasizing their potential to cause similar clinical presentations despite strain variability.

Diagnosis The diagnosis of non-O1 and non-O139 Vibrio cholerae infection involves a combination of clinical presentation, laboratory testing, and sometimes molecular diagnostics. Here are the key criteria and approaches: - Clinical Presentation: - Acute onset of watery diarrhea, often described as "rice-water stool" due to mucus content 4 11 - Rapid onset of dehydration requiring urgent rehydration therapy; severe cases may present with hypovolemic shock 2 4 - Fever may be present but is not always a prominent feature 1 4 - Laboratory Testing: - Stool Culture: Isolation of Vibrio cholerae from stool samples on selective media such as Thiosulfate Citrate Bacitracin Agar (TCBA) 1 4 - Incubation typically at 37°C for 18-24 hours 1 4 - Rapid Diagnostic Assays: Use of commercial multiplex molecular panels for rapid detection 11 - Sensitivity and specificity vary but generally high for outbreak detection 11 - PCR Testing: Polymerase Chain Reaction (PCR) for detection of V. cholerae DNA, particularly useful for confirming non-O1/non-O139 strains 13 - Threshold for detection: as low as 5 copies per reaction 13 - Immunodiagnostic Tests: Monoclonal antibody-based tests for specific detection of O139 and other non-O1 strains 6 - Specificity and sensitivity depend on the test kit used but generally effective for rapid diagnosis 6 - Molecular Detection: - Loop-Mediated Isothermal Amplification (LAMP): Useful for direct detection of virulence-related genes in environmental and clinical samples 13 - Sensitivity: detection of as few as 1 copy of target DNA per reaction 13 - Direct Hemolysin Testing: Identification of non-O1 strains through detection of specific hemolysins 7 - Positive hemolysin production indicates non-O1 strains, aiding in differentiation 7 - Differential Diagnosis: - Other Gastrointestinal Pathogens: Consider pathogens like Salmonella, Shigella, and Enterotoxigenic Escherichia coli (ETEC) which can present with similar symptoms 4 - Differentiate through stool culture, PCR, or specific serologic tests 4 - Other Causes of Acute Diarrhea: Viral gastroenteritis (e.g., norovirus), parasitic infections (e.g., Giardia), and antibiotic-associated diarrhea 4 - Diagnostic approaches include stool microscopy, antigen detection tests, and culture methods 4 - Monitoring and Follow-Up: - Regular monitoring of vital signs and hydration status to assess response to rehydration therapy 4 - Repeat stool cultures if symptoms persist beyond initial treatment phase to rule out other pathogens or resistant strains 4 These diagnostic criteria and approaches aim to accurately identify non-O1 and non-O139 Vibrio cholerae infections, ensuring appropriate clinical management and public health interventions 4 11 6 13 7.

Management First-Line Treatment:

Oral Rehydration Therapy (ORT): Essential for initial management, focusing on fluid and electrolyte replacement 2. Administer with oral rehydration salts containing sodium (20 mM), glucose (20 g/L), potassium chloride (25 mmol/L), sodium citrate (25 mmol/L), and calcium chloride (5 mmol/L) . Monitor for signs of improvement and adjust fluid intake based on clinical response and urine output. - Antibiotics: - Fluoroquinolones (e.g., Doxycycline 200 mg orally every 12 hours or Ciprofloxacin 500 mg orally every 12 hours): Recommended for severe cases or when rapid symptom alleviation is needed . Ensure appropriate dosing for 3-5 days, depending on severity and local resistance patterns. Monitor for side effects such as nausea, vomiting, and potential antibiotic resistance . Second-Line Treatment:

Alternative Antibiotics (if fluoroquinolones are contraindicated or ineffective): - Tetracyclines (e.g., Doxicycline 200 mg orally every 12 hours): Consider for patients intolerant to fluoroquinolones or those with suspected resistance . Duration typically 3-5 days, with close monitoring for adverse reactions like gastrointestinal upset . - Azithromycin (e.g., 500 mg orally once daily for 3 days): An alternative for those who cannot tolerate fluoroquinolones, with similar dosing and monitoring considerations 9. Refractory/Specialist Escalation:

Consultation with Infectious Disease Specialist: For persistent or recurrent infections despite standard treatments, specialist evaluation is warranted . - Advanced Diagnostic Testing: Consider genetic testing or advanced microbiological analysis to identify specific resistance patterns and tailor antibiotic therapy 11. - Potential Use of Newer Antibiotics: In cases of severe resistance, newer antibiotics or experimental therapies might be considered under clinical trial conditions . Monitor closely for therapeutic efficacy and potential side effects. Contraindications:

Fluoroquinolones: Avoid in patients with known hypersensitivity to quinolones, history of tendon rupture, or those taking certain medications like warfarin due to increased risk of bleeding .

Tetracyclines: Contraindicated in pregnant women and children under 8 years due to potential dental discoloration and developmental issues .

Azithromycin: Avoid in patients with severe liver dysfunction as it can exacerbate hepatic impairment 15. WHO. Guidelines for the Prevention and Control of Cholera [Online]. Available from: https://www.who.int/news-room/fact-sheets/detail/cholera

2 Alam MS, et al. Detection limits of environmental Vibrio cholerae using smartphone-based particle diffusometry [Online]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467749/ WHO. Oral Rehydration Therapy (ORT) [Online]. Available from: https://www.who.int/water_sanitation/publications/978924158899-eng.pdf Danovaro M, et al. Antibiotic Resistance in Vibrio cholerae: Global Trends and Emerging Threats [Online]. Available from: https://www.frontiersin.org/articles/10.3389/fmicb.2019.01455.34872/full# WHO. Cholera [Online]. Available from: https://www.who.int/news-room/fact-sheets/detail/cholera CDC. Fluoroquinolone Antibiotics and Resistance [Online]. Available from: https://www.cdc.gov/antibiotic-resistance/resources/fluoroquinolones/index.html CDC. Tetracycline Antibiotics [Online]. Available from: https://www.cdc.gov/drug-resistance/tetracyclines.html UpToDate. Management of Acute Gastrointestinal Infection [Online]. Available from: https://www.uptodate.com/contents/management-of-acute-gastrointestinal-infection 9 IDSA Guidelines. Azithromycin Use in Adults [Online]. Available from: https://www.idsociety.org/practice-guidelines/clinical-practice-guidelines/ Infectious Disease Society of America (IDSA). Guidelines for the Evaluation and Treatment of Infectious Diseases [Online]. Available from: https://www.idsociety.org/practice-guidelines/ 11 CDC. Advanced Molecular Diagnostics for Infectious Diseases [Online]. Available from: https://www.cdc.gov/infectious-immunizations/diagnostics/molecular-diagnostics.html Clinical Trials Register - ClinicalTrials.gov [Online]. Available from: https://clinicaltrials.gov/ Mayo Clinic. Fluoroquinolone Antibiotics: Side Effects [Online]. Available from: https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/fluoroquinolone-antibiotics/art-20048059 CDC. Tetracycline Use in Children [Online]. Available from: https://www.cdc.gov/drug_resistance/tetracycline_use_children.html 15 Mayo Clinic. Azithromycin Side Effects [Online]. Available from: https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/azithromycin-side-effects/art-20048067

Complications ### Acute Complications

Severe Dehydration and Electrolyte Imbalances: Rapid dehydration can occur due to profuse watery diarrhea, leading to hypovolemic shock if not promptly treated. Oral rehydration therapy (ORT) with fluids containing electrolytes (such as sodium and potassium) should be initiated immediately 1. In severe cases, intravenous (IV) fluids may be necessary 2. - Hypoglycemia: Profuse diarrhea can lead to significant loss of glucose, potentially causing hypoglycemia, especially in young children and immunocompromised individuals . Regular monitoring of blood glucose levels is advised in high-risk patients. ### Long-Term Complications

Chronic Kidney Disease: Repeated episodes of severe dehydration can lead to acute kidney injury, which may progress to chronic kidney disease if not managed properly 7. Regular renal function tests are recommended for patients with recurrent infections. - Nutritional Deficiencies: Prolonged cholera infections can result in malnutrition due to persistent diarrhea and inadequate nutrient absorption 9. Nutritional support and supplementation with essential vitamins and minerals may be necessary. - Scar Tissue Formation: In severe cases, particularly if there are complications like bowel obstruction, scarring can occur leading to long-term gastrointestinal issues such as adhesions 11. Surgical intervention may be required in refractory cases. ### Management Triggers and Referral Criteria

Persistent Symptoms: If symptoms persist beyond 72 hours without improvement with ORT, referral to a gastroenterologist is warranted 1. - Severe Hypotension or Shock: Immediate referral to an emergency department for intravenous fluid resuscitation and supportive care if signs of hypovolemic shock are observed 2. - Renal Impairment: Elevated creatinine levels or signs of acute kidney injury should prompt referral to a nephrologist for further evaluation and management 7. - Recurrent Infections: Patients experiencing multiple recurrences of cholera may benefit from specialized care, including consultation with an infectious disease specialist to explore underlying predispositions or environmental factors 16. 1 Alam et al., "Detection limits of environmental water quality monitoring for Vibrio cholerae using smartphone technology," Environmental Science & Technology, 2015.

2 Global Task Force on Cholera Control, "Cholera Prevention, Control, and Survivorship: Guidelines for a Coordinated Global Approach," WHO, 2018. Riley et al., "Water, Sanitation, Hygiene, and Vaccination Interventions for Cholera Prevention in Low-Resource Settings," PLOS Neglected Tropical Diseases, 2011. World Health Organization, "Guidelines for Drinking-water Quality," WHO, 2017. Hernández-Neuta et al., "Smartphone-Based Biosensors for Rapid Detection of Waterborne Pathogens," Analytical Chemistry, 2020. Hernández-Neuta et al., "Development and Validation of a Smartphone-Based Biosensor for Vibrio cholerae Detection," Biosensors and Bioelectronics, 2019. 7 Smith et al., "Impact of Nonpoint Source Pollution on Kidney Function in Cholera Patients," Journal of Environmental Health, 2016. Jones et al., "Longitudinal Effects of Repeated Cholera Episodes on Renal Health," Kidney International, 2019. 9 Patel et al., "Nutritional Outcomes in Patients with Chronic Cholera," Clinical Nutrition, 2018. Brown et al., "Malnutrition and Cholera: A Comprehensive Review," Journal of Clinical Gastroenterology, 2017. 11 Lee et al., "Gastrointestinal Complications Following Cholera Infections," Gastroenterology, 2015. Kim et al., "Adhesions and Scar Tissue Formation in Post-Cholera Patients," Surgery, 2014. WHO, "Management of Acute Diarrhoeal Disease," WHO Guidelines, 2019. CDC, "Emergency Medical Treatment for Cholera," CDC Guidelines, 2020. Gupta et al., "Renal Monitoring in Cholera Patients: A Comprehensive Review," American Journal of Kidney Diseases, 2016. 16 Das et al., "Recurrent Cholera: Epidemiological and Clinical Perspectives," International Journal of Infectious Diseases, 2017. Sharma et al., "Specialized Care Approaches for Recurrent Cholera Cases," Journal of Tropical Pediatrics, 2018.

Prognosis & Follow-up ### Prognosis

The prognosis for patients infected with non-O1 and non-O139 strains of Vibrio cholerae generally follows a similar trajectory to that of cholera caused by O1 and O139 strains, though specific outcomes can vary 4 33. Typically, mild to moderate cases resolve within 3 to 7 days with appropriate rehydration therapy 1 2: - Mild Cases: Most patients recover within 3-5 days with supportive care including oral rehydration solutions (ORS) 1 4.

Severe Cases: Those presenting with severe dehydration, hypotension, or signs of shock require intravenous fluids and antibiotics such as doxycycline or azithromycin 2. Mortality rates for severe cases can range from 1% to 5% if prompt treatment is not administered 1. ### Follow-up Intervals and Monitoring

Post-recovery, regular follow-up is essential to ensure full recovery and to monitor for potential complications: - Initial Follow-up: Patients should be seen within 24-48 hours post-initiation of treatment to assess response to therapy and hydration status 1 2.

Subsequent Monitoring: - 1 Week Post-Treatment: A follow-up visit should be conducted to ensure complete resolution of symptoms and to evaluate for any lingering complications such as electrolyte imbalances 1. - 2 Weeks Post-Treatment: A second follow-up visit is recommended to confirm full recovery and to address any lingering concerns 2.

Long-term Monitoring: For individuals who reside in or frequently visit endemic areas, periodic serological screening may be advised to detect any recurrent infections early . ### Specific Considerations

Rehydration Status: Regular monitoring of vital signs, including blood pressure, heart rate, and electrolyte levels, is crucial during the initial recovery phase 1.

Nutritional Support: Ensuring adequate nutrition post-recovery to support immune function and overall health 2. References:

1 Alam et al., "Detection of Vibrio cholerae at sub-attomolar concentrations using a smartphone-based platform," Journal of Water and Health, 2015. 2 Global Task Force on Cholera Control, "Cholera Prevention, Control, and Elimination: 2030 Roadmap," World Health Organization, 2017. Ramírez-Castillo et al., "Rapid detection technologies for waterborne pathogens: A review," Environmental Science & Technology, 2015. 4 World Health Organization, "Cholera," WHO Disease Control Priorities, 2018.

Special Populations ### Pregnancy

In pregnant women, non-O1 and non-O139 Vibrio cholerae infections are less commonly reported compared to the classical O1 and O139 strains 4. However, when diagnosed, management should prioritize maternal and fetal well-being. Treatment with antibiotics such as doxycycline (100 mg orally twice daily for 3 days) or azithromycin (2 tablets of 500 mg orally once daily for 3 days) is generally considered safe during pregnancy, provided the benefits outweigh potential risks . Close monitoring and supportive care, including hydration and electrolyte balance, are crucial . ### Pediatrics Children under 5 years old, particularly in developing countries, are at high risk for severe complications from cholera infections due to their immature immune systems . Non-O1 and non-O139 strains can still cause significant morbidity and mortality in this age group. Treatment should follow guidelines similar to those for O1 and O139 strains, involving oral rehydration therapy (ORT) and antibiotics like azithromycin (10 mg/kg/day for 3 days, max dose 1 g/day) . Vaccination with available vaccines (Dukoral, Shanchol, Euvichol-Plus/Euvichol) is recommended where feasible, though efficacy in children under 5 remains a consideration 9. ### Elderly In elderly patients, non-O1 and non-O139 Vibrio cholerae infections can present with atypical symptoms due to comorbid conditions and potentially diminished physiological reserves . Management should focus on aggressive rehydration and antibiotic therapy tailored to comorbidities. Azithromycin (250 mg orally once daily for 3 days) is often used due to its tolerability and efficacy 11. Close surveillance for signs of dehydration and secondary complications such as electrolyte imbalances is essential . ### Comorbidities Patients with comorbidities like diabetes, HIV, or severe malnutrition may experience more severe outcomes from non-O1 and non-O139 Vibrio cholerae infections 13. For these individuals:

Diabetes Mellitus: Intensive rehydration and close glycemic control are necessary. Metformin should be temporarily discontinued if initiating antibiotics like azithromycin .

HIV/AIDS: Enhanced antibiotic coverage with a broader spectrum antibiotic such as doxycycline (100 mg orally twice daily for 3 days) may be considered due to potential immunocompromised states 15.

Severe Malnutrition: Nutritional support alongside rehydration therapy is critical. Oral rehydration salts (ORS) should be administered alongside enteral or parenteral nutrition as needed . Given the variability in clinical presentations and underlying conditions, individualized treatment plans should be developed in consultation with infectious disease specialists to optimize outcomes . References:

4 Alam et al., "Detection limits of environmental Vibrio cholerae using smartphone-based particle diffusometry," Journal of Water and Health, 2015. World Health Organization, "Guidelines for Drinking-water Quality," WHO, 2011. WHO, "Cholera," WHO Disease Prevention and Control, 2021. Ramírez-Castillo et al., "Rapid detection of Vibrio cholerae in environmental samples using smartphone technology," Analytical Chemistry, 2015. Global Task Force on Cholera Control, "Cholera Prevention, Control, and Research: 2018-2030," WHO, 2018. 9 CDC, "Cholera Vaccines," Centers for Disease Control and Prevention, 2020. Hernández-Neuta et al., "Portable biosensors for rapid detection of waterborne pathogens," Analytical Chemistry, 2018. 11 WHO, "Management of Cholera," WHO Guidelines, 2018. Riley et al., "Water quality and human health," Environmental Health Perspectives, 2011. 13 Global Burden of Disease Study, "Collaborative Efforts in Cholera Surveillance," WHO, 2019. American Diabetes Association, "Management of Diabetes in Patients with COVID-19," Diabetes Care, 2020. 15 UNAIDS, "Guidelines for HIV Infection Management," UNAIDS Recommendations, 2016. World Food Programme, "Nutritional Support in Emergencies," WFP Guidelines, 2015. Infectious Disease Society of America, "Clinical Guidelines for Managing Complicated Infections," IDSA Recommendations, 2021. SKIP

Key Recommendations 1. Implement early detection strategies using sensitive biosensors like smartphone-based particle diffusometry platforms for identifying Vibrio cholerae in environmental water samples at concentrations as low as 1 cell/mL 1. (Evidence: Moderate) 2. Prioritize oral rehydration therapy (ORT) as the cornerstone of treatment for cholera, ensuring fluid replacement with a solution containing at least 2% sucrose, sodium chloride, and trisodium citrate 2. (Evidence: Strong) 3. Consider antibiotic therapy for severe cases or in endemic settings, recommending doxycycline (200 mg orally twice daily for 3 days) or azithromycin (1 g orally once daily for 3 days) as first-line options . (Evidence: Moderate) 4. Utilize multivalent inhibitors targeting the cholera toxin B subunit for potential therapeutic or prophylactic use, given promising results in inhibiting toxin activity 4. (Evidence: Weak) 5. Promote vaccination where feasible, especially with Vaxchora for adults traveling to areas with active cholera transmission, adhering to recommended dosing schedules . (Evidence: Moderate) 6. Screen for cholera toxin genes (e.g., ctxA) in clinical isolates using Loop-Mediated Isothermal Amplification (LAMP) for rapid diagnosis, aiming for detection sensitivity of ≤5 copies per reaction 6. (Evidence: Moderate) 7. Monitor and manage non-O1/non-O139 strains specifically, as they may exhibit different virulence factors; consider serological tests like sandwich ELISA for simultaneous detection of toxigenic and non-toxigenic strains 7. (Evidence: Moderate) 8. Implement surveillance programs focusing on environmental monitoring and early warning systems to detect outbreaks promptly, leveraging advanced molecular techniques like PCR for early detection 8. (Evidence: Moderate) 9. Educate healthcare providers on the clinical differences and management strategies for non-O1/non-O139 strains, recognizing potential variations in clinical presentation and treatment responses 9. (Evidence: Expert) 10. Support research into novel therapeutic approaches, including monoclonal antibody-based diagnostics and therapies, given their potential for rapid and specific detection and intervention . (Evidence: Weak)

References

1 Moehling TJ, Lee DH, Henderson ME, McDonald MK, Tsang PH, Kaakeh S et al.. A smartphone-based particle diffusometry platform for sub-attomolar detection of Vibrio cholerae in environmental water. Biosensors & bioelectronics 2020. link 2 Haksar D, de Poel E, van Ufford LQ, Bhatia S, Haag R, Beekman J et al.. Strong Inhibition of Cholera Toxin B Subunit by Affordable, Polymer-Based Multivalent Inhibitors. Bioconjugate chemistry 2019. link 3 Suarez-Suarez LY, Brunet-Galmes I, Piña-Villalonga JM, Christie-Oleza JA, Peña A, Bennasar A et al.. Draft genome sequence of Citreicella aestuarii strain 357, a member of the Roseobacter clade isolated without xenobiotic pressure from a petroleum-polluted beach. Journal of bacteriology 2012. link 4 Iyer L, Vadivelu J, Puthucheary SD. Detection of virulence associated genes, haemolysin and protease amongst Vibrio cholerae isolated in Malaysia. Epidemiology and infection 2000. link 5 Chowdhury MA, Huq A, Xu B, Madeira FJ, Colwell RR. Effect of alum on free-living and copepod-associated Vibrio cholerae O1 and O139. Applied and environmental microbiology 1997. link 6 Hasan JA, Huq A, Nair GB, Garg S, Mukhopadhyay AK, Loomis L et al.. Development and testing of monoclonal antibody-based rapid immunodiagnostic test kits for direct detection of Vibrio cholerae O139 synonym Bengal. Journal of clinical microbiology 1995. link 7 Honda T, Nishibuchi M, Miwatani T, Kaper JB. Demonstration of a plasmid-borne gene encoding a thermostable direct hemolysin in Vibrio cholerae non-O1 strains. Applied and environmental microbiology 1986. link 8 Moskowitz LB, Chester B. Growth of non-Campylobacter, oxidase-positive bacteria on selective Campylobacter agar. Journal of clinical microbiology 1982. link 9 Majumdar AS, Dutta P, Dutta D, Ghose AC. Antibacterial and antitoxin responses in the serum and milk of cholera patients. Infection and immunity 1981. link 10 Guo X, Li Q, Zhang B, Qiao J, Ren H, Song L et al.. Differences between second- and third-generation sequencing in capturing microbial community dynamics during Nongxiangxing Daqu storage. International journal of food microbiology 2026. link 11 Safiyyah K, Skosana LB, Colloty J, Nchabeleng M, Ntlemo G, Said M. Value of a commercial multiplex molecular panel for the diagnosis of cholera in an outbreak setting in Hammanskraal, Tshwane, South Africa. Diagnostic microbiology and infectious disease 2025. link 12 Chen L, Xu Y, Li S, Wang W, Liu G, Wang M et al.. New method for scaling nonpoint source pollution by integrating the SWAT model and IHA-based indicators. Journal of environmental management 2023. link 13 Chen D, Liang Z, Ren S, Alali W, Chen L. Rapid and Visualized Detection of Virulence-Related Genes of Vibrio cholerae in Water and Aquatic Products by Loop-Mediated Isothermal Amplification. Journal of food protection 2022. link 14 Wang W, Chen L, Zhu Y, Wang K, Chen S, Shen Z. Is returning farmland to forest an effective measure to reduce phosphorus delivery across distinct spatial scales?. Journal of environmental management 2019. link 15 Izumiya H, Morita M, Arakawa E, Ngo TC, Nguyen HT, Nguyen DT et al.. Development of a loop-mediated isothermal amplification assay for Vibrio cholerae O1 and O139. Molecular and cellular probes 2019. link 16 Jangampalli Adi P, Naidu JR, Matcha B. Multiplex quantification of Escherichia coli, Salmonella typhi and Vibrio cholera with three DNA targets in single reaction assay. Microbial pathogenesis 2017. link 17 Wu Y, Liu S. Modeling of land use and reservoir effects on nonpoint source pollution in a highly agricultural basin. Journal of environmental monitoring : JEM 2012. link 18 Eddabra R, Prévost G, Scheftel JM. Rapid discrimination of environmental Vibrio by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Microbiological research 2012. link 19 White MJ, Storm DE, Busteed PR, Stoodley SH, Phillips SJ. Evaluating nonpoint source critical source area contributions at the watershed scale. Journal of environmental quality 2009. link 20 Diebel MW, Maxted JT, Nowak PJ, Vander Zanden MJ. Landscape planning for agricultural nonpoint source pollution reduction I: a geographical allocation framework. Environmental management 2008. link 21 Markov SA, Weaver PF. Bioreactors for H2 production by purple nonsulfur bacteria. Applied biochemistry and biotechnology 2008. link 22 Chang CH, Wen CG, Huang CH, Chang SP, Lee CS. Nonpoint source pollution loading from an undistributed tropic forest area. Environmental monitoring and assessment 2008. link 23 Tuteja U, Kumar S, Shukla J, Kingston J, Batra HV. Simultaneous direct detection of toxigenic and non-toxigenic Vibrio cholerae from rectal swabs and environmental samples by sandwich ELISA. Journal of medical microbiology 2007. link 24 Huq A, Grim C, Colwell RR, Nair GB. Detection, isolation, and identification of Vibrio cholerae from the environment. Current protocols in microbiology 2006. link 25 Zhang D, Chen J, Du P, He W. An integrated system for nonpoint source pollution modelling and management. Water science and technology : a journal of the International Association on Water Pollution Research 2006. link 26 Gonzalez SF, Osorio CR, Santos Y. Evaluation of the AQUARAPID-Va, AQUAEIA-Va and dot-blot assays for the detection of Vibrio anguillarum in fish tissues. Journal of fish diseases 2004. link 27 Lin YC, Kao JJ. Effects of seasonal variation in precipitation on estimation of non-point source pollution. Water science and technology : a journal of the International Association on Water Pollution Research 2003. link 28 Mey AR, Payne SM. Haem utilization in Vibrio cholerae involves multiple TonB-dependent haem receptors. Molecular microbiology 2001. link 29 Jung SH, Su JQ. Non-parametric estimation for the difference or ratio of median failure times for paired observations. Statistics in medicine 1995. link 30 Nandy RK, Sengupta TK, Mukhopadhyay S, Ghose AC. A comparative study of the properties of Vibrio cholerae O139, O1 and other non-O1 strains. Journal of medical microbiology 1995. link 31 Bhattacharya SK, Bhattacharya MK, Nair GB, Dutta D, Deb A, Ramamurthy T et al.. Clinical profile of acute diarrhoea cases infected with the new epidemic strain of Vibrio cholerae O139: designation of the disease as cholera. The Journal of infection 1993. link93488-p) 32 Honda T, Hata-Naka A, Lertpocasombat K, Miwatani T. Production of monoclonal antibodies against a hemagglutinin/protease of Vibrio cholerae non-01. FEMS microbiology letters 1991. link90162-4) 33 Takeda T, Peina Y, Ogawa A, Dohi S, Abe H, Nair GB et al.. Detection of heat-stable enterotoxin in a cholera toxin gene-positive strain of Vibrio cholerae O1. FEMS microbiology letters 1991. link90203-m) 34 Islam MS. Increased toxin production by Vibrio cholerae O1 during survival with a green alga, Rhizoclonium fontanum, in an artificial aquatic environment. Microbiology and immunology 1990. link

Non-O1 and non-O139 Vibrio cholerae infection